The United State’s (U.S.) Food and Drug Administration (FDA) has approved Cabenuva cabotegravir and rilpivirine for every two months dosing for the treatment of HIV-1.
This was disclosed by the U.S. HIV specialist pharmaceutical company ViiV Healthcare on Wednesday
The treatment is for HIV in virologically suppressed adults on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.
ViiV Healthcare is majority-owned by GlaxoSmithKline plc, with Pfizer and Shionogi Limited as shareholders.
Cabenuva is the first and only complete long-acting HIV treatment regimen and was first approved by the U.S. FDA in January 2021 as a once-monthly treatment for HIV-1 in virologic ally suppressed adults.
The U.S. FDA approval allows Cabenuva to be dosed monthly or every two months.
Long-acting cabotegravir and rilpivirine are approved for use every two months in Canada under the name Cabenuva and in the EU as Vocabria and Rekambys.
